Research and Markets (http://www.researchandmarkets.com/research/145e0c/pipeline_insight)
has announced the addition of the "Pipeline
Insight: Multiple Sclerosis - Risk-benefit ratio under the spotlight for
potent pipeline drugs" report to their offering.
“Pipeline
Insight: Multiple Sclerosis - Risk-benefit ratio under the spotlight for
potent pipeline drugs”
Sales of multiple sclerosis disease-modifying therapies exceeded $6.0
billion in 2008 across the seven major markets (US, Japan, France,
Germany, Italy, Spain and the UK). Datamonitor anticipates the
combination of continuing strong historical growth dynamics and the
uptake of the first oral therapies to result in the market value peaking
at $8.4 billion in 2013 before the advent of biosimilars.
Scope
-
Analysis of multiple sclerosis diagnosis, treatment, prevalence
trends, and key unmet market needs.
-
Review of the late-stage disease-modifying multiple sclerosis
pipeline, including analysis of key R&D company strategies.
-
In depth analysis of historic (2004-08) and future (2009-2018) seven
major market sales value dynamics.
-
Commercial and clinical assessment of key late-stage pipeline drugs,
with key opinion leader comment and region-specific sales forecasts to
2018.
Highlights of this title
Although there are number of exciting developments present in the
late-stage pipeline, the risk-benefit ratio of the leading candidates
remains uncertain. In a situation reminiscent of Tysabri (natalizumab,
Biogen Idec/Elan), potent efficacy has been accompanied by an increased
risk of adverse events compared to first-line currently marketed drugs.
With impressive efficacy data, and despite incidents of malignancies,
Datamonitor expects the two most advanced oral developments, Mylinax
(oral cladribine; Merck Serono) and fingolimod (FTY720; Novartis) to
become first-line therapies. With seven major market sales of $1.2
billion, fingolimod is forecast to become the new market leader in 2018.
Late-stage trial results suggest that Campath (alemtuzumab;
Genzyme/Bayer Schering) is the most efficacious MS treatment to date.
With the final positioning strategy unclear, Datamonitor believes
Campath is most likely to be restricted to the short-term treatment of
severe early cases and rapidly-progressive forms of MS because of safety
concerns.
Key reasons to purchase this title
-
Analyze competitive environment at time of product launch.
-
Validate internal forecasts and market potential for pipeline products.
-
Identify licensing opportunities based on company portfolio and market
needs.
Key Topics Covered: